Axial Spondyloarthritis | Unmet Need | Ankylosing Spondylitis | US/EU | 2024
In the last two decades, TNF-α inhibitors (AbbVie’s Humira, Amgen/Pfizer’s Enbrel, Johnson & Johnson Innovative Medicine’s Remicade and Simponi, and UCB’s Cimzia) have transformed the treatment of ankylosing spondylitis (AS) and brought new attention to this autoimmune disease. The IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz) are relatively new to AS treatment but provide an alternative approach to TNF-α inhibition. Oral targeted therapies such as JAK inhibitors (AbbVie’s Rinvoq and Pfizer’s Xeljanz) are also approved for AS. This report delves into areas of remaining unmet need in AS treatment and offers insight into commercial opportunities and the potential for emerging therapies to meet these needs.
Questions answered
- What are the treatment drivers and goals for AS?
- Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for AS?
- What are the prevailing areas of unmet need and opportunity in AS?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new AS drug?
Product description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Key feature:
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 32 European rheumatologists fielded in December 2023
Key companies: AbbVie, Amgen, Johnson & Johnson Innovative Medicine, UCB, Novartis, Eli Lilly
Key drugs: Humira, Enbrel, Remicade, Cimzia, Cosentyx, Taltz, Rinvoq
